Editas Medicine (EDIT) Preferred Stock Liabilities (2015)
Editas Medicine (EDIT) reported Preferred Stock Liabilities of $21.1 million for Q4 2015.
Editas Medicine (EDIT) has 1 years of Preferred Stock Liabilities data on file, last reported at $21.1 million in Q4 2015.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $21.1 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $21.1 million (changed N/A YoY) and the FY2015 annual result came in at $21.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $21.1 million in Q4 2015 per EDIT's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $21.1 million in Q4 2015 and bottomed at $21.1 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 21.14 Mn |